Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses ALLK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALLK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Alexander | $805,460 | $0 | $2,171,340 | $2,623,519 | $684,641 | $0 | $14,466 | $6,299,426 |
| Chief Executive Officer and Director | ||||||||
| Adam Tomasi | 709,670 | 0 | 1,411,178 | 1,705,059 | 425,802 | 0 | 14,466 | 4,266,175 |
| President | ||||||||
| Baird Radford | 494,400 | 0 | 911,808 | 1,101,693 | 222,480 | 0 | 14,466 | 2,744,847 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Robert Alexander | $6,299,426 | $7,367,405 | $10,989,677 | −1,067,979 |
| Adam Tomasi | 4,266,175 | 4,955,570 | 7,259,414 | −689,395 |
| Baird Radford | 2,744,847 | 3,361,165 | 6,019,663 | −616,318 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Baird Radford | OPTION | 2023-01-06 | — | — | 194,144 | — | $1,101,693 |
| Robert Alexander | RSU | 2023-01-06 | — | — | 301,575 | — | 2,171,340 |
| Adam Tomasi | OPTION | 2023-01-06 | — | — | 300,471 | — | 1,705,059 |
| Robert Alexander | OPTION | 2023-01-06 | — | — | 462,325 | — | 2,623,519 |
| Adam Tomasi | RSU | 2023-01-06 | — | — | 195,997 | — | 1,411,178 |
| Baird Radford | RSU | 2023-01-06 | — | — | 126,640 | — | 911,808 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Baird Radford | $911,808 | $0 | $1,101,693 | 0.0% |
| Robert Alexander | 2,171,340 | 0 | 2,623,519 | 0.0% |
| Adam Tomasi | 1,411,178 | 0 | 1,705,059 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adam Tomasi | RSU | 19,625 | — | $53,576 |
| Adam Tomasi | RSU | 16,681 | — | 45,539 |
| Robert Alexander | RSU | 297,745 | — | 812,844 |
| Adam Tomasi | RSU | 193,534 | — | 528,348 |
| Adam Tomasi | RSU | 195,997 | — | 535,072 |
| Baird Radford | RSU | 133,655 | — | 364,878 |
| Robert Alexander | RSU | 30,400 | — | 82,992 |
| Robert Alexander | PSU | 17,227 | — | 47,030 |
| Adam Tomasi | PSU | 11,121 | — | 30,360 |
| Baird Radford | RSU | 6,413 | — | 17,507 |
| Robert Alexander | Option | 462,325 | 7.2 | — |
| Baird Radford | Option | 194,144 | 7.2 | — |
| Baird Radford | Option | 9,200 | 105.16 | — |
| Baird Radford | RSU | 126,640 | — | 345,727 |
| Robert Alexander | RSU | 25,841 | — | 70,546 |
| Baird Radford | RSU | 12,128 | — | 33,109 |
| Adam Tomasi | PSU | 344,060 | — | 939,284 |
| Robert Alexander | RSU | 301,575 | — | 823,300 |
| Adam Tomasi | Option | 300,471 | 7.2 | — |
| Robert Alexander | PSU | 529,323 | — | 1,445,052 |
| Baird Radford | PSU | 237,608 | — | 648,670 |
The guiding principle in the development of our compensation strategy is to create and nurture a pay-for-performance culture, where contributions to enhancing stockholder value have the potential to be matched with appropriate financial rewards.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | False |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| E. Rand SutherlandIndependent · Research and Clinical Development · Not standing for re-election | $18,333 | $0 | $714,142 | — | $0 | $732,475 |
| Dolca ThomasIndependent · Research and Clinical Development | 18,333 | 0 | 714,142 | — | 0 | 732,475 |
| Daniel JanneyIndependent · Board Chair · Compensation · Corporate Governance and Nominating (Chair) · Not standing for re-election | 112,500 | 0 | 322,117 | — | 0 | 434,617 |
| Robert E. AndreattaIndependent · Audit (Chair) · Corporate Governance and Nominating | 67,500 | 0 | 322,117 | — | 0 | 389,617 |
| Steven P. JamesIndependent · Audit · Corporate Governance and Nominating | 65,000 | 0 | 322,117 | — | 0 | 387,117 |
| Paul WalkerIndependent · Audit · Compensation | 65,000 | 0 | 322,117 | — | 0 | 387,117 |
| Neil GrahamIndependent · Research and Clinical Development | 13,750 | 0 | 364,525 | — | 0 | 378,275 |
| Amy L. LaddIndependent · Compensation · Corporate Governance and Nominating | 50,000 | 0 | 322,117 | — | 0 | 372,117 |
| John McKearnIndependent · Departed during FY | 32,500 | 0 | — | — | 0 | 32,500 |
| Robert AlexanderEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $47,500 |
|---|---|
| Annual equity retainer | $296,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $442,916 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $442,916 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Allakos names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Allakos.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 4 | Allakos | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 5 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 6 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 7 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 8 | Omeros Corporation | 2025 | Gregory Demopulos | 972,525 | 0 | 2,207,974 | 0 | 4,178,008 |
| 9 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 10 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 11 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | Outlook Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Annexon, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | PMV Pharmaceuticals, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Fulcrum Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Allakos | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | 85% | Options 55 · RSU 25 · PSU 20 | No | Compensia |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Annexon, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Fulcrum Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Kiniksa Pharmaceuticals, Ltd. | 181% | Options 50 · RSU 25 · PSU 25 | Yes — relative ranking of the TSR of our Class A Shares relative to the NBI | Compensia, Inc. |
| Kodiak Sciences Inc. | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Mersana Therapeutics, Inc. | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Omeros Corporation | 100% | Options 100 | not disclosed | Compensia |
| Outlook Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| PMV Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Alexander | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 2 | Section 01, Adam Tomasi | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 4,266,175. Filing ↗machine: r8 · c26 · span 546255–546264 |
| 3 | Section 01, Baird Radford | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 2,744,847. Filing ↗machine: r5 · c26 · span 525677–525686 |
| 4 | Section 03, Baird Radford OPTION | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r7 · c25 · span 613559–613568 |
| 5 | Section 03, Robert Alexander RSU | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r3 · c24 · span 585655–585664 |
| 6 | Section 03, Adam Tomasi OPTION | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r10 · c25 · span 633943–633952 |
| 7 | Section 03, Robert Alexander OPTION | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r4 · c25 · span 592508–592517 |
| 8 | Section 03, Adam Tomasi RSU | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r9 · c24 · span 627093–627102 |
| 9 | Section 03, Baird Radford RSU | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r6 · c24 · span 606486–606493 |
| 10 | Section 08, E. Rand Sutherland | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 732,475. Filing ↗machine: t25 · r7 · c11 · span 1144284–1144291 |
| 11 | Section 08, Dolca Thomas | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 732,475. Filing ↗machine: t25 · r8 · c11 · span 1147549–1147556 |
| 12 | Section 08, Daniel Janney | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 434,617. Filing ↗machine: t25 · r2 · c11 · span 1127979–1127986 |
| 13 | Section 08, Robert E. Andreatta | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 389,617. Filing ↗machine: t25 · r3 · c11 · span 1131241–1131248 |
| 14 | Section 08, Steven P. James | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 387,117. Filing ↗machine: t25 · r5 · c11 · span 1137753–1137760 |
| 15 | Section 08, Paul Walker | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 387,117. Filing ↗machine: t25 · r4 · c11 · span 1134495–1134502 |
| 16 | Section 08, Neil Graham | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 378,275. Filing ↗machine: t25 · r9 · c11 · span 1150813–1150820 |
| 17 | Section 08, Amy L. Ladd | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 372,117. Filing ↗machine: t25 · r6 · c11 · span 1141013–1141020 |
| 18 | Section 08, John McKearn | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 32,500. Filing ↗machine: t25 · r10 · c3 · span 1152140–1152146 |
| 19 | Section 08, Robert Alexander | DEF 14A | 2024-04-23 | 0000950170-24-047043 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 21 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 22 | Section 09b board cost (computed) | Computed | — | computed | Cash 442,916 + equity 0 + all other 0 = 442,916, summed across the director compensation table rows.machine: formula: Σ = 442,916 |
| 23 | Cogent Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 24 | Immunovant, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 25 | Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001104659-26-044410 | CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. Filing ↗machine: t182 · r7 · c14 · span 755082–755092 |
| 26 | Allakos (subject), Section 10b CEO total | DEF 14A | 2024-04-23 | 0000950170-24-047043 | CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 27 | Allogene Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 28 | AnaptysBio, Inc., Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 29 | Celldex Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 30 | Omeros Corporation, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001552781-26-000281 | CEO total compensation as printed in Omeros Corporation's own proxy. As printed: 4,178,008. Filing ↗machine: t160 · r1 · c6 · span 462502–462511 |
| 31 | Kodiak Sciences Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 32 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 33 | Mersana Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 34 | Section 10a, AnaptysBio, Inc. reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 35 | Section 10a, Kiniksa Pharmaceuticals, Ltd. reciprocity | DEF 14A | — | 0001104659-26-044410 | Kiniksa Pharmaceuticals, Ltd.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 36 | Section 10a, Kodiak Sciences Inc. reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 37 | Section 10a, Omeros Corporation reciprocity | DEF 14A | — | 0001552781-26-000281 | Omeros Corporation's most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 38 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 39 | Section 10a, Mersana Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 40 | Section 10a, Allogene Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 41 | Section 10a, Celldex Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 42 | Section 10a, Cogent Biosciences, Inc. reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |
| 43 | Section 10a, Immunovant, Inc. reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗ |